| Title | Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases. |
| Author(s) | Gish P, Mosholder AD, Truffa M, Johann-Liang R |
| Institution | Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, The United States Food and Drug Administration, Silver Spring, MD 20993, USA. paula.gish@fda.hhs.gov |
| Source | J Pediatr 2009 Sep; 155(3):432-4. |
| MeSH | Adolescent
Adult
Adverse Drug Reaction Reporting Systems
Age Factors
Central Nervous System
Child
Child, Preschool
Databases as Topic
Humans
Infant
Mandelic Acids
Middle Aged
Muscarinic Antagonists
Nervous System Diseases
Nocturnal Enuresis
Young Adult
|
| Abstract | We reviewed Food and Drug Administration postmarketing reports of central nervous system (CNS) anticholinergic effects in association with oxybutynin. Taking domestic usage by age group into account, there is a disproportionately higher number of CNS adverse event cases reported in pediatric patients as compared with adult patients. CNS stimulation was prominent in the pediatric cases. |
| Language | eng |
| Pub Type(s) | Comparative Study
Journal Article
|
| PubMed ID | 19732583 |
